Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Day One Biopharmaceuticals (DAWN) EBITDA: 2023-2025

Historic EBITDA for Day One Biopharmaceuticals (DAWN) over the last 3 years, with Sep 2025 value amounting to -$24.3 million.

  • Day One Biopharmaceuticals' EBITDA fell 181.83% to -$24.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$165.6 million, marking a year-over-year increase of 21.67%. This contributed to the annual value of -$217.3 million for FY2024, which is 5.44% down from last year.
  • Latest data reveals that Day One Biopharmaceuticals reported EBITDA of -$24.3 million as of Q3 2025, which was up 30.66% from -$35.0 million recorded in Q2 2025.
  • In the past 5 years, Day One Biopharmaceuticals' EBITDA registered a high of $29.6 million during Q3 2024, and its lowest value of -$114.8 million during Q2 2024.
  • For the 3-year period, Day One Biopharmaceuticals' EBITDA averaged around -$47.4 million, with its median value being -$48.6 million (2023).
  • In the last 5 years, Day One Biopharmaceuticals' EBITDA surged by 157.61% in 2024 and then slumped by 181.83% in 2025.
  • Quarterly analysis of 3 years shows Day One Biopharmaceuticals' EBITDA stood at -$59.5 million in 2023, then declined by 9.77% to -$65.3 million in 2024, then tumbled by 181.83% to -$24.3 million in 2025.
  • Its EBITDA was -$24.3 million in Q3 2025, compared to -$35.0 million in Q2 2025 and -$41.1 million in Q1 2025.